University of Thessaly (UTH)
Συχνότητα αυτοαντισωμάτων σε πρώτου βαθμού συγγενείς ασθενών με αυτοάνοσα νοσήματα του ήπατος
Abstract
dc:descriptionPrimary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown cause characterized by immune-mediated destruction of the intrahepatic bile ducts, gradually leading to fibrosis, cirrhosis, and eventually, liver failure. Early detection of PBC is important, since patients with PBC, albeit asymptomatic, have reduced overall survival compared to controls, while timely treatment with ursodeoxycholic acid before the development of late-stage disease normalizes life expectancy. The observed differences in PBC prevalence between populations living in different geographical regions but sharing similar genetic background support that environmental factors play a pivotal role in disease etiology. Epidemiologic evidence suggests several non-genetic risk factors to be associated with PBC, including a history of urinary tract infections (UTI), past smoking and use of hormone replacement therapy. Conversely, genetic factors also play an important role in conferring susceptibility to PBC, as indicated by the high concordance rate among monozygotic twins and the increased prevalence of PBC and other autoimmune disorders in patients’ families. During the past 15 years, several studies have reported familial PBC prevalence to range between 1.3% and 9%. In addition to clustering of PBC and other autoimmune diseases in the families of PBC patients, the presence of antimitochondrial antibodies (AMA) aggregates in first-degree relatives of afflicted individuals as well, with AMA prevalence ranging between 1 and 13.1%. In addition to AMA, previous studies have shown that antinuclear antibodies (ANA) giving a multiple nuclear dot (MND) and a rim-lime/membranous (RL/M) pattern by indirect immunofluorescence (IIF) are found in up to 25% of PBC patients and are shown to be disease specific and have prognostic significance. Although several studies have estimated AMA prevalence in first-degree relatives (FDRs) of PBC patients, little is known about the association of AMA with exposure to risk factors for PBC or prevalence of disease specific ANA in this population. Furthermore, significant variation in AMA prevalence in FDRs exists according to the population tested and the method used for AMA detection. The aim of the present study was to determine the prevalence of AMA and ANA in FDRs of patients with PBC and investigate their association with known comorbidities and reported risk factors for PBC. A total of 101 FDRs of 44 PBC patients (8 of them with AMA-negative PBC) agreed to participate in the study. The control group consisted of 40 FDRs of patients with autoimmune hepatitis-1 (AIH-1) or primary sclerosing cholangitis (PSC) and 40 blood donors with unremarkable medical history, who were age-matched to the FDR group. Using IIF, AMA were detected in 24.1% of the FDRs and none of the controls. The prevalence of AMA was 27.7% in FDRs of patients with PBC and 15% in FDRs of patients with AIH-1 or PSC, however this difference was not statistically significant. PBC FDRs had significantly increased AMA-positivity compared to healthy controls. IgG AMA were detected in 11.9% of the PBC FDRs by the MIT3-based M2 Elisa, whereas none of the AIH-1/PSC FDRs or the healthy controls were positive for AMA. On rat multiorgan substrate, ANA positivity was observed in 4% of PBC relatives compared to 12.5% of AIH-1/PSC relatives, however this difference was not statistically significant. Antibodies causing a RLM pattern on Hep-2 cells, were observed in 15.8% of PBC FDRs. A RLM pattern was, also, observed in one PSC FDR and in none of the controls (p<0.05 and p<0.01, respectively). All serum samples were further evaluated with an anti-gp210 ELISA, however anti-gp210 reactivity was not observed. Notably, a MND pattern was observed in significantly more AIH-1/PSC FDRs than PBC FDRs (27.5% vs. 12.9%). Nevertheless, the prevalence of MND pattern was significantly higher in FDRs of PBC patients than healthy controls (12.9% vs. 0%, p<0.05). Using an ELISA assay, anti-sp100 positivity was observed in one PSC FDR, whereas the remaining study population were anti-sp100 negative. The PBC FDR group included 20 FDRs of probands with AMA-negative PBC. There was no significant difference in the prevalence of AMA between FDRs of patients with AMA-negative PBC and FDRs of patients with AMA-positive PBC (20% vs. 29.6%, p=0.389). The data reported herein demonstrate that FDRs of patients with PBC have increased prevalence of AMA and disease-specific ANA compared to healthy controls. We have also provided evidence that AMA positivity may be present in FDRs of PBC patients with AMA-negative PBC. In the studies investigating autoantibody prevalence in relatives of PBC patients, AMA were reported ranging between 4.9% and 7.5% of the screened relatives, with the exception of a study from Brazil which estimated AMA prevalence in FDRs to be 1%. In the most comprehensive study of FDRs of PBC patients, Lazaridis et al reported AMA positivity in 13.1% of the FDRs and 1% of the healthy controls. Using a M2 ELISA, we have observed similar rates of AMA positivity (11.9%) in our study population.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zografos, Theodoros
- Ζωγράφος, Θεόδωρος
Subjects
dc:subject × 14- Πρωτοπαθής χολική κίρρωση
- Αυτοάνοση ηπατίτιδα (ΑΗ)
- Πρωτοπαθής σκληρυντική χολαγγειίτιδα
- Αυτοαντισώματα
- Primary biliary cirrhosis
- Autoimmune hepatitis
- Primary sclerosing cholangitis
- Autoantibodies
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Ιατρική Βιοτεχνολογία
- Medical and Health Sciences
- Clinical Medicine
- Medical Biotechnology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/28616